目的评价新型全降解聚乳酸西罗莫司洗脱支架(XinsorbTM)在小型猪冠状动脉抑制新生内膜增殖的有效性和安全性。方法裸金属支架(Bare metal stent,BMS)16枚和Xinsorb支架16枚分别随机置入16头小型猪的前降支(16枚)和右冠状动脉(16枚)。置...目的评价新型全降解聚乳酸西罗莫司洗脱支架(XinsorbTM)在小型猪冠状动脉抑制新生内膜增殖的有效性和安全性。方法裸金属支架(Bare metal stent,BMS)16枚和Xinsorb支架16枚分别随机置入16头小型猪的前降支(16枚)和右冠状动脉(16枚)。置入30d和90d,复查冠状动脉造影后处死部分动物取出支架段血管,将支架分成等长的两部分,一半用树脂包埋后制作硬组织切片,苏木素和伊红染色(haematoxylin and eosin,HE)分析组织形态,评价新生内膜增殖及管腔狭窄率;另一半用戊二醛固定后用扫描电镜观察支架段血管内皮化情况。结果 Xinsorb支架置入后未出现支架内血栓,并有效防止血管弹性回缩造成的血管狭窄。病理分析提示:置入30d,Xinsorb支架比BMS能显著减少新生内膜面积(0.9±0.2)mm2比(2.2±0.2)mm2(P<0.05)和管腔狭窄面积(19.3±3.4)%比(38.2±5.3)%(P<0.05),置入30d时BMS内皮化完全,但Xinsorb支架表面有部分未完全内皮化,Xinsorb支架内皮化完全所需的时间在30～90d。结论 Xinsorb支架在置入小型猪冠状动脉90d内,可以有效地支撑血管壁防止弹性回缩并抑制新生内膜增殖,在置入早期轻度延迟内皮的修复。展开更多
A fused hirudin peptide was designed, synthesized and purified and its antithrombin and antiplatelet functions were tested.This bifunctional anticoagulation peptide was composed of three inhibitory regions: (1)the tai...A fused hirudin peptide was designed, synthesized and purified and its antithrombin and antiplatelet functions were tested.This bifunctional anticoagulation peptide was composed of three inhibitory regions: (1)the tail of hirudin (hirudin 53-64 ), a potent direct antithrombin , binds to the anion binding exosite (ABE) of thrombin.Hirudin 53-64 blocks fibrinogen recognition site of thrombin and consequently inhibits thrombin directly;(2) Arg -Pro -Pro -Gly - Phe (RPPGF) amino acid sequence, a metabolite of bradykinin,binds to the active site of thrombin and thereby inhibits the amidolytic activity of thrombin;(3)Arg-Gly-Asp(RGD)amino acid sequence, an inhibitor of GP IIb/IIIa, blocks the final path of platelets aggregation by preventing fibrinogen binding to platelets. This 26 amino acid fused hirudin peptide was artificially synthesized, purified and analysed.The study finally showed that the fused hirudin peptide had activities of antithrombin and antiplatelet. It is feasible to construct a hybrid multifunctional peptide that targets various components of haemostatic process.展开更多
文摘目的评价新型全降解聚乳酸西罗莫司洗脱支架(XinsorbTM)在小型猪冠状动脉抑制新生内膜增殖的有效性和安全性。方法裸金属支架(Bare metal stent,BMS)16枚和Xinsorb支架16枚分别随机置入16头小型猪的前降支(16枚)和右冠状动脉(16枚)。置入30d和90d,复查冠状动脉造影后处死部分动物取出支架段血管,将支架分成等长的两部分,一半用树脂包埋后制作硬组织切片,苏木素和伊红染色(haematoxylin and eosin,HE)分析组织形态,评价新生内膜增殖及管腔狭窄率;另一半用戊二醛固定后用扫描电镜观察支架段血管内皮化情况。结果 Xinsorb支架置入后未出现支架内血栓,并有效防止血管弹性回缩造成的血管狭窄。病理分析提示:置入30d,Xinsorb支架比BMS能显著减少新生内膜面积(0.9±0.2)mm2比(2.2±0.2)mm2(P<0.05)和管腔狭窄面积(19.3±3.4)%比(38.2±5.3)%(P<0.05),置入30d时BMS内皮化完全,但Xinsorb支架表面有部分未完全内皮化,Xinsorb支架内皮化完全所需的时间在30～90d。结论 Xinsorb支架在置入小型猪冠状动脉90d内,可以有效地支撑血管壁防止弹性回缩并抑制新生内膜增殖,在置入早期轻度延迟内皮的修复。
文摘A fused hirudin peptide was designed, synthesized and purified and its antithrombin and antiplatelet functions were tested.This bifunctional anticoagulation peptide was composed of three inhibitory regions: (1)the tail of hirudin (hirudin 53-64 ), a potent direct antithrombin , binds to the anion binding exosite (ABE) of thrombin.Hirudin 53-64 blocks fibrinogen recognition site of thrombin and consequently inhibits thrombin directly;(2) Arg -Pro -Pro -Gly - Phe (RPPGF) amino acid sequence, a metabolite of bradykinin,binds to the active site of thrombin and thereby inhibits the amidolytic activity of thrombin;(3)Arg-Gly-Asp(RGD)amino acid sequence, an inhibitor of GP IIb/IIIa, blocks the final path of platelets aggregation by preventing fibrinogen binding to platelets. This 26 amino acid fused hirudin peptide was artificially synthesized, purified and analysed.The study finally showed that the fused hirudin peptide had activities of antithrombin and antiplatelet. It is feasible to construct a hybrid multifunctional peptide that targets various components of haemostatic process.
